www.elsevier.com/locate/buildenv

Asmbs Integrated Health Nutritional Guidelines For The Surgical Weight Loss Patient — 2016 Update: Micronutrients

Julie Parrott, Laura Frank, Rebecca Dilks, Lillian Craggs-Dino, Kellene A. Isom, Laura Greiman

PII: S1550-7289(16)30882-6
DOI: http://dx.doi.org/10.1016/j.soard.2016.12.018
Reference: SOARD2866

To appear in: *Surgery for Obesity and Related Diseases*

Cite this article as: Julie Parrott, Laura Frank, Rebecca Dilks, Lillian Craggs-Dino, Kellene A. Isom and Laura Greiman, Asmbs Integrated Health Nutritional Guidelines For The Surgical Weight Loss Patient — 2016 Update: Micronutrients, *Surgery for Obesity and Related Diseases,* http://dx.doi.org/10.1016/j.soard.2016.12.018

ASMBS INTEGRATED HEALTH NUTRITIONAL GUIDELINES FOR THE SURGICAL WEIGHT LOSS PATIENT — 2016 UPDATE: MICRONUTRIENTS

Julie Parrott, MS, RDN[1]

Laura Frank, PhD, MPH, RD, CD[2]

Rebecca Dilks RD, LDN[3]

Lillian Craggs-Dino, DHA, RDN, LDN[4]

Kellene A. Isom, MS, RD, LDN[5]

Laura Greiman, MPH, RD[6]

[1]Clinical Director, Formulas for Fitness, NJ; [2] Frank Nutrition and Exercise Consulting, Gig Harbor, WA; [3]Exos Performance Dietitian, Philadelphia, PA; [4]Bariatric Dietitian and Support Group Coordinator, Cleveland Clinic Florida, Weston, FL; [5]Bariatric Program Manager, Center for Metabolic and Bariatric Surgery, Brigham and Women's Hospital, Boston, MA; [6]Clinical Dietitian, Surgical Weight Loss Program, Sharp Memorial Hospital, San Diego, CA

Corresponding author: Julie Parrott

Clinical Director, Formulas for Fitness, 51 Sandburg Dr., Morganville, NJ 07751, 732-939-7147, jparrott06@gmail.com

Acknowledgments:

We would like to thank Dr. Stephanie Sogg, Chair of the ASMBS Integrated Health Clinical Issues and Guidelines committee for her oversight and editing, advice and support. We thank our peer reviewers: Sue Cummings and Dr. Ann Rogers, and the encouraging guidance provided by Research Methodologist, Dr. James S. Parrott. We also thank the American Society for Metabolic and Bariatric Surgery Executive Council and the Integrated Health Executive Council.

Abstract

Background: Optimizing postoperative patient outcomes and nutritional status begins preoperatively. Patients should be educated before and after weight loss surgery (WLS) on the expected nutrient deficiencies associated with alterations in physiology. Even though, surgery can exacerbate pre-existing nutrient deficiencies, preoperative screening for vitamin deficiencies has not been the norm in the majority of WLS practices. Screening is important, as it is common for patients presenting for WLS to have at least one vitamin or mineral deficiency-preoperatively.

Objectives: The focus of this paper has been to up-date the 2008 ASMBS Nutrition in Bariatric Surgery guidelines with key micronutrient research in laparoscopic adjustable gastric banding (LAGB), Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastrectomy (SG), biliopancreatic diversion (BPD), and BPD/duodenal switch (BPD/DS).

Methods: Four questions regarding the recommendations for preoperative and postoperative screening of nutrient deficiencies; preventative supplementation and repletion of nutrient deficiencies in pre-WLS patients have been applied to specific micronutrients (vitamin B1, vitamin B12, folate, iron, vitamins A, E, K, calcium, vitamin D, copper, and zinc).

Results: Out of the 554 articles identified as meeting preliminary search critera, 402 publications were reviewed in detail. There are 92 recommendations in this update; 79 new recommendations and an additional 13 recommendations that have not changed since 2008. Each recommendation has a corresponding graded level of evidence from Grade A through D.

Conclusions: Data continues to suggest that the prevalence of micronutrient deficiencies is increasing, while at the same time, monitoring of patients in follow-up is decreasing. This document should be viewed as a guideline for a reasonable approach to patient nutritional care based on the most recent research, scientific evidence, resources, and information available. It is the responsibility of the registered dietitian nutritionist (RD/RDN) and weight loss surgery program to determine individual variations as they relate to patient nutritional care.

DISCLAIMER

The American Society for Metabolic and Bariatric Surgery (ASMBS) is established as an educational professional medical society. This document is intended to update the 2008 ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient.[1] These guidelines are based on expert opinion as well as a literature review of empirical and

clinical data and are not intended to serve as training, standard of care, or scientific consensus.

INTRODUCTION

The role of the registered dietitian nutritionist (RD/RDN) continues to be a vital component of the WLS process. Recent guidelines recommend that all patients pursuing WLS should undergo a preoperative clinical nutrition evaluation by an RD. [2] This evaluation is necessary to identify preoperative nutritional deficiencies, as well as to evaluate patients' ability to incorporate nutritional changes before and after WLS.[1] These guidelines also recommend including medical nutrition therapy for all bariatric patients as an essential component of comprehensive health care. Medical nutrition therapy, provided by RDs, incorporates a systematic four-step Nutrition Care Process (NCP). This process is dynamic and ongoing and consists of: 1) nutrition assessment, 2) nutrition diagnosis, 3) nutrition intervention and 4) monitoring and evaluation.[3, 4] This paper is intended to facilitate all four steps of this process by focusing on the pre- and post-WLS assessment, supplementation and repletion of micronutrient deficiencies.

In 2008, the American Society for Metabolic and Bariatric Surgery (ASMBS) Nutrition Committee published the Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient.[1] Prior to the publication of this guideline there were no uniform nutritional guidelines available for WLS patients. The 2008 guidelines[1] provided some standardization across surgical practices, but considerable variation remains. While much of the content of this document remains relevant, clinical and empirical knowledge of

nutritional care of patients pursuing WLS is ever increasing. What follows is an update based on current literature review.

The term "WLS", as is it used in this Clinical Practice Guideline (CPG), is meant to encompass the metabolic and physiological changes of bariatric surgery. Various bariatric and metabolic procedures are performed in patients, in need of weight loss and metabolic control. Laparoscopic procedures are preferred, due to their lower rates of morbidity and mortality. Laparoscopic adjustable gastric banding (LAGB), Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastrectomy (SG), biliopancreatic diversion (BPD), and BPD/duodenal switch (BPD/DS) are the primary procedures performed. These procedures have traditionally been classified as restrictive, malabsorptive, or combination procedures, based on their mechanisms for weight loss and metabolic control. [5] However, the early, weight-independent effects of RYGB, BPD/DS, and SG on glucose control for patients with pre-diabetes or Type II DM (TDM) is a strong indicator supporting the metabolic nature of these surgeries. Since the mechanisms of bariatric surgery are continuing to be elucidated, we will use WLS to encompass "bariatric and metabolic surgery".[6, 7]

Optimizing postoperative patient outcomes and nutritional status begins preoperatively.[1-3, 8] Patients should be educated before and after WLS on the expected nutrient deficiencies associated with alterations in physiology, especially involving nutrient digestion, absorption, metabolism and excretion.[9] Even though, surgery can exacerbate pre-existing nutrient deficiencies, preoperative screening for vitamin deficiencies has not been the norm in the majority of WLS practices.[10] Screening is important, as it is common for patients presenting for WLS to have at least one vitamin or mineral deficiency-preoperatively.[11] Data continue to suggest that the prevalence of micronutrient

deficiencies is increasing, while at the same time, monitoring of patients in follow-up is decreasing.[10-13]

ORGANIZATION OF THE GUIDELINES

The following guideline narrative is organized into sections by micronutrient with subsections corresponding to four domains: Preoperative Screening, Postoperative Screening, Supplementation, and Repletion for Deficiencies. Evidence for recommendations is presented in each of these sections. The content covered within each section differs somewhat due to the nature of the developing research and extent of available data regarding each micronutrient. The evidence discussed for each micronutrient is, therefore, not completely standardized but follows the emphases and new developments within each of the fields of research. Summaries of all recommendations are graded by level of supporting evidence and are available in Tables 1-4.

Further detail and resources for application (assessment and treatment options) are provided in Table 5 and 6.

METHODS

Clinical Guidelines Workgroup and Question Identification

The literature reviews involved in preparing this document followed standards set out in both the AACE/TOS/ASMBS Protocol for Standardized Production of Clinical Practice Guidelines[14], and by The Institute of Medicine (IOM).[15] Selection of the chair, primary writers, and reviewers, as well as the process for creating this evidence-based clinical practice guideline were conducted in accordance with the ASMBS Process for Developing

Clinical Practice Guidelines and using the four-step grading approach outlined in the American Association of Clinical Endocrinologists (AACE) Protocol for Standardized Production of Clinical Practice Guidelines—2010 Update.[14] After questions were developed for the update, a systematic review of the literature was conducted. Four questions applied to each of the micronutrients discussed (vitamin B1, vitamin B12, folate, iron, vitamins A, E, K, calcium, vitamin D, copper, and zinc), guided the literature search in updating the 2008 ASMBS nutrition guidelines:

Q1: What is the recommendation for preoperative screening of nutrient deficiencies in patients who plan to have WLS? (Table 1)

Q2: What is the recommendation for postoperative screening of nutrient deficiencies in patients who have had WLS? (Table 2)

Q3: What are the supplement recommendations to help prevent nutrient deficiencies in patients who have had WLS? (Table 3)

Q4: What are the repletion recommendations to treat nutrient deficiencies in patients who have had WLS? (Table 4)

The 2008 Nutrition Guidelines included several topics that are still valid and did not require updating: (1) preoperative nutrition assessment, (2) preoperative nutrition education, and (3) diet and texture progression. Topics that were outside the scope of this current update include restriction versus malabsorption and an update for protein and other macronutrients. There are recent publications addressing some nutrition-related aspects of macronutrients. [16, 17] Vitamin B6, selenium, and magnesium, briefly mentioned in 2008 as "other micronutrients" were not updated; whereas copper has been

added, due to its intertwined relationship with zinc and the potential impact on WLS patients.

Search Methods

Electronic Database Searches

The Integrated Health Clinical Issues and Guidelines Nutrition Subcommittee conducted a literature search for articles related to WLS and specific nutrients. The specific search terms included "bariatric" or "weight loss" and "surgery", as well as all of the most commonly performed bariatric procedures, including LAGB, RYGB, SG, and BPD/DS. These were combined with each of the nutrients of interest (e.g., calcium).

The search was limited to relevant literature focusing on humans, adults age 18 years or older, published in English, between January 1, 2007 and April 1, 2016, with a sample size greater than 10 patients, except for pertinent case studies. Earlier literature was included on an *ad hoc* basis, determined by relevance.

Other Evidence Sources

This review also incorporates existing sets of published guidelines relevant to the nutritional care of the WLS patient, including the combined AACE, the Obesity Society (TOS), and ASMBS sponsored guidelines.[2]

Search Results

In total, 554 articles were initially identified of which 471 articles were found to be relevant and were screened. Of these articles, 402 publications were reviewed in detail (Appendix A). Search results identified meta-analyses of randomized and non-randomized controlled trials (MRCT and NRCT); randomized controlled trials (RCT); meta-analyses of nonrandomized prospective or case-controlled trials (MNRCT); prospective and

retrospective cohort studies (PCT/RCS/RCCS); cross-sectional studies (CSS); systematic reviews, clinical practice guidelines (CPG); epidemiological/survey studies (SS); consecutive case series (CCS) and single case reports (SCR).

Hierarchy of Evidence

Risk of bias and level of confidence was evaluated using the AACE Protocol for Standardized Production of Clinical Practice Guideline hierarchy of evidence framework. [14] Each article was assigned an evidence level (see Appendices B-E). This hierarchy does not include all possible types of study design. Studies reviewed that did not fall under the AACE hierarchy were integrated into our own hierarchy, guided by the Oxford Centre for Evidence Based Medicine's levels of evidence framework.[18]

Recommendation Formulation and Grading

Recommendations were formulated for each domain within each micronutrient category, with reference to the previous guidelines. Once this was completed, the grading strategy published by AACE was followed to provide consistent and systematic grades with strongest to weakest levels noted as A through D and best evidence level (BEL)from strongest to weakest levels noted as 1-4 for each recommendation.*[14]* There are 92 recommendations in this update; 79 new recommendations (noted by ☑ in Tables 1-4); and an additional 13 recommendations that have not changed since 2008.[1] Each recommendation has a corresponding graded level of evidence:

- Grade A =Strong (4 ☑ ; 0 not changed)
- Grade B= Intermediate (29 ☑ ; 3 not changed)
- Grade C = Weak (33 ☑; 2 not changed)
- Grade D = "No evidence" (13 ☑; 8 not changed)

Recommendation Tables 1-6 (please see separate Word docs)

Micronutrients: Evidence And Recommendations (please see Supplementary materials)

SUMMARY

This paper is an update for the American Society for Metabolic and Bariatric Surgery (ASMBS) Nutrition Committee's Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient (2008)[1] and serves as an educational tool for not only dietitians, but other providers working with pre-WLS patients. The focus of this paper has been to up-date the guideline with findings from current literature regarding key micronutrient deficiencies and WLS. As evidence-based guidelines continue to be updated and recommendations become more established into the daily practice of perioperative nutrition care, it will be important to investigate differences in responders to treatment and new potential mechanisms explaining changes in nutrient status. Additionally, controlling for confounding factors (such as dietary intake of nutrients from both food and supplements, food-medication interactions, food-nutrient interactions, and if, how, and by whom nutrition assessment and counseling is conducted) in nutrient-related studies will increase the rigor of data collection and consistency in the quality of research reported.

The Nutrition Committee of the Integrated Health Clinical Issues and Guidelines Committee of the ASMBS sincerely hopes that this document will serve to enhance the general nutrition knowledge necessary for the care of the pre- and postoperative patient, with consideration for the individual patient's unique medical needs, as well as the variable protocols established among surgical centers and individual practices.

AUTHORS' DISCLOSURES — POTENTIAL CONFLICTS OF INTEREST

Anonymous

Acknowledgments:

Anonymous

Appendices A-D (please see supplementary material)

REFERENCES

[1] Allied Health Sciences Section Ad Hoc Nutrition C, Aills L, Blankenship J, Buffington C, Furtado M, Parrott J. ASMBS Allied Health Nutritional Guidelines for the Surgical Weight Loss Patient. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2008;4:S73-108. EL 4, NE, CPG

[2] Mechanick JI, Youdim A, Jones DB, Timothy Garvey W, Hurley DL, Molly McMahon M, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2013;9:159-91. EL 4, NE; CPG

[3] Parrott J, Parrott JS. 2014.Nutrition Care Across the Weight Loss Surgery Spectrum. In: Still CSD, Blankenship J.: Springer. EL 4, NE Book chapter

[4] Academy of Nutrition and Dietetics.2016.Nutrition Care Process. June 9, 2016.2016.http://www.eatrightpro.org/resources/practice/nutrition-care-process EL 4, NE

[5] American Association of Clinical Endocrinologists/the American College of E, Obesity S, Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society: executive summary. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2013;19:875-87. EL 4, NE, CPG

[6] Corcelles R, Daigle CR, Schauer PR. Management of Endocrine Disease: Metabolic effects of bariatric surgery. European journal of endocrinology / European Federation of Endocrine Societies. 2016;174:R19-28. EL 4, NE Review

[7] Sarosiek K, Pappan KL, Gandhi AV, Saxena S, Kang CY, McMahon H, et al. Conserved Metabolic Changes in Nondiabetic and Type 2 Diabetic Bariatric Surgery Patients: Global Metabolomic Pilot Study. Journal of diabetes research. 2016;2016:3467403. EL 2, NRCT; Small sample size in each group; total sample size = 15

[8] Martindale RG, McClave SA, Taylor B, Lawson CM. Perioperative nutrition: what is the current landscape? JPEN Journal of parenteral and enteral nutrition. 2013;37:5S-20S. EL 4, NE

[9] Weight Management Dietetic Practice Group; Sue Cummings M, RD, LDN, and Kellene A. Isom, MS, RD, LDN. Pocket Guide to Bariatric Surgery. Journal. 2015. EL 4, NE

[10] Gudzune KA, Huizinga MM, Chang HY, Asamoah V, Gadgil M, Clark JM. Screening and diagnosis of micronutrient deficiencies before and after bariatric surgery. Obesity surgery. 2013;23:1581-9. EL 3, SS

[11] Gehrer S, Kern B, Peters T, Christoffel-Courtin C, Peterli R. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study. Obesity surgery. 2010;20:447-53. EL 2, PCS

[12] Bal BS, Finelli FC, Shope TR, Koch TR. Nutritional deficiencies after bariatric surgery. Nature reviews Endocrinology. 2012;8:544-56. EL 4, NE Review

[13] Peterson LA, Cheskin LJ, Furtado M, Papas K, Schweitzer MA, Magnuson TH, et al. Malnutrition in Bariatric Surgery Candidates: Multiple Micronutrient Deficiencies Prior to Surgery. Obesity surgery. 2016;26:833-8. EL 3, CSS

[14] Mechanick JI, Camacho PM, Cobin RH, Garber AJ, Garber JR, Gharib H, et al. American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2010;16:270-83. EL 4, NE CPG

[15] Institute of Medicine, (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines: Clinical Practice Guiidelines We Can Trust. Standards for Developing Trustworthy Clinical Practice Guidelines. Journal. 2011. EL 4, NE CPG

[16] Bays HE, Jones PH, Jacobson TA, Cohen DE, Orringer CE, Kothari S, et al. Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: FULL REPORT. J Clin Lipidol. 2016;10:33-57. EL 4, NE Review

[17] Bays H, Kothari SN, Azagury DE, Morton JM, Nguyen NT, Jones PH, et al. Lipids and bariatric procedures Part 2 of 2: scientific statement from the American Society for Metabolic and Bariatric Surgery (ASMBS), the National Lipid Association (NLA), and Obesity Medicine Association (OMA). Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 2016;12:468-95. EL 4, NE Review

[18] University of Oxford Centre for Evidence-based Medicine.2015.OCEBM Levels of Evidence. June 25, 2015.2015.http://www.cebm.net/ocebm-levels-of-evidence. EL 4, NE

ASMBS Nutrition CPG List of Abbreviations

Academy Of Nutrition And Dietetics (AND)
Acute Phase Reactant (APR)
Acute Post-Gastric Reduction Surgery (APGARS)
Adequate Intake (AI)
Adjustable Gastric Band (Agb)
American Association Of Clinical Endocrinologists (AACE)
American Society For Metabolic And Bariatric Surgery (ASMBS)
American Society For Parenteral And Enteral Nutrition (ASPEN)
Biliopancreatic Diversion With Duodenal Switch BPD/DS
Carboxy-Terminal Telopeptide (CTX)
Case Reports (CS)
Clinical Practice Guideline (CPG)
Consecutive Case Series (CCS)
Cross-Sectional Studies (CSS)
Deciliter (DL)
Daily Value (DV)
Dual-energy x-ray absorptiometry (DXA)
Des-Gamma-Carboxy Prothrombin (DCP)
Dietary Reference Intake (DRI)
Duodenal Switch (Ds)
European Federation Of Neurological Societies (EFNS)
Gastrointestinal (GI)
Gram (Gm)
Homocysteine (Hcy)
Institute Of Medicine (IOM)
Intact Parathyroid Hormone (Ipth)
International Unit (IU)
Intramuscular (IM)
Intravenous (IV)
Iron (Fe)
Liter (L)
Medical Nutrition Therapy (Mnt)
Meta-Analysis Non-Randomized Controlled Trial (MNRCT)
Meta-Analysis Randomized Controlled Trials (MRCT)
Methyl Malonic Acid (MMA)
Microgram (Mcg)
Milligram (Mg)
Milliliter (Ml)
No Evidence (Theory, Opinion, Consensus, Or Review) (NE)
Nutrition Care Process (NCP)
Nutrition-Focused Physical Assessment (NFPA)

Office Of Dietary Supplements (ODS)
Parathyroid Hormone (PTH)
Picogram (Pg)
Prospective Cohort Studies (PCS)
Proton Pump Inhibitors (Ppis)
Randomized Controlled Trials (RCT)
Recommended Dietary Allowance (RDA)
Red Blood Cell (RBC)
Registered Dietitian (RD)
Retrospective Cohort Studies (RCS/RCCS)
Roux-En-Y Gastric Bypass (RYGB),
Sleeve Gastrectomy (Sg)
Small Bowel Bacterial Overgrowth (SBBO)
Surveillance Study (Registries, Surveys, Epidemiologic Study) (SS)
The Obesity Society (Tos)
Thiamin Deficiency (TD)
Thiamin, whole blood (TDP)
Thiamin Pyrophosphate (TPP)
Tolerable Upper Intake Level (UL)
Total Iron Binding Capacity (TIBC)
Transferrin Saturation (Tsat)
Type 1 Collagen N-Telopeptide (NTX)
Upper Intake Level (UL)
Vitamin D Deficiency (VDD)
Vitamin D Insufficiency (VDI)
Weight Loss Surgery (WLS)
Wernicke-Korsakoff Syndrome (Wks)
Wernicke's Encephalopathy (WE)

Table 1: Pre-WLS Nutrient Screening Recommendations

Micronutrient	Pre-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
Thiamin	• Routine pre-WLS screening* is recommended in all patients. (Grade C, BEL 3)* ☑	• Prevalence of thiamin deficiency (TD) pre-WLS is reported to be as high as 29%	• Thiamin diphosphate (TDP), the biologically active form of thiamin, is not found in measurable concentrations in plasma, and is best determined in whole blood specimens. Plasma thiamin concentration reflects recent intake rather than body stores. Thiamin carried by albumin will be decreased with concomitant hypoalbuminemia.
Vitamin B12 (Cobalamin)	• Routine pre-WLS screening of B12 is recommended for all patients. (Grade B, BEL 2) ☑ • Serum MMA is the recommended assay for B12 evaluation for symptomatic or asymptomatic patients and in those with history of B12 deficiency or pre-existing neuropathy. (Grade B, BEL 2) ☑	• Prevalence of B12 deficiency is reported to be between 2-18% in patients with obesity and 6-30% in patients taking proton pump inhibitors (PPI).	• Serum B12 levels alone may not be adequate to identify B12 deficiency. • Elevated MMA levels (values >0.4 micromol/L) may be a more reliable indicator of B12 status because it indicates a metabolic change that is highly specific to B12 deficiency.
Folate (Folic Acid)	• Routine pre-WLS screening is recommended in all patients.	• Prevalence of folate	• ↓RBC folate and ↑serum

Micronutrient	Pre-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
	(Grade B, BEL 2) ☑	deficiency is reported to be as high as 54% in patients with obesity.	homocysteine and normal MMA levels indicate folate deficiency
Iron	• Routine pre-WLS screening is recommended for all patients. (Grade B, BEL 2) ☑ • Screening patients for iron status, but not for the purpose of diagnosing iron deficiency, may include the use of ferritin levels. (Grade B, BEL 2) ☑ • A combination of tests (serum iron with serum transferrin saturation and total iron-binding capacity) is recommended for diagnosing iron deficiency. (Grade B, BEL 2) • Screening for iron deficiency should include assessment of clinical signs and symptoms common to this condition (e.g. feeling tired and weak, decreased work performance, decreased immune function and glossitis). (Grade B, BEL 2)	• Prevalence of iron deficiency is reported to be as high as 45% in patients with obesity.	• Ferritin levels should not be used to diagnose deficiency as iron is an acute phase reactant and may fluctuate with age, inflammation and infection. • Lab tests indicate iron deficiency if iron <50 μg/dL ferritin <20 μg/dL TIBC>450 μg/dL
Vitamin D and Calcium	• Routine pre-WLS screening is recommended in all patients. (Grade A, BEL 1) ☑ • Routine pre-WLS screening of calcium status, vitamin D deficiency and insufficiency is particularly important for pre- and post-menopausal women. (Grade D, BEL 4) ☑	• Prevalence of Vitamin D deficiency is reported to be as high as 90% in patients with obesity. • Elevated values of carboxy-terminal telopeptide (CTX) have been reported in 66.7 % of patients under 50 years of age.	• Use a combination of laboratory tests: vitamin D, 25-OH, serum alkaline phosphatase, PTH, and 24-hour urinary calcium in relationship to dietary intake. • Peri-and post-menopausal women may be screened for increased bone resorption by using urinary

Micronutrient	Pre-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
			and/or serum type I collagen N-telopeptide (NTX) levels, which are higher in patients with decreasing estrogen production.
Fat soluble vitamins (A E, K)	• Routine pre-WLS screening is recommended in all patients. (Grade C, BEL 3) ☑	• Prevalence of deficiencies pre-WLS is reported to be: • Vitamin A 14% • Vitamin E 2.2 % • There are no data on vitamin K deficiencies in pre-WLS patients	• Use physical signs and symptoms and labs (Table 5) for: ○ *Vit A deficiency*: ↓Retinol Binding Protein (RBP) and ↓plasma retinol ○ *Vit E deficiency*: ↓plasma α-tocopherol ○ *Vit K deficiency*: ↑DCP
Zinc	• Routine pre-WLS screening of zinc status is recommended for patients prior to RYGB or BPD/DS. (Grade D, BEL 3) ☑ • Zinc assays in pre-WLS patients should be interpreted in light of the fact that patients with obesity have lower serum zinc levels and lower concentrations of zinc in plasma and erythrocytes than leaner patients. Thus, repletion of zinc is indicated when signs and symptoms are evident and zinc assays are severely low. (Grade C, BEL 3) ☑	• Prevalence of zinc deficiency is reported to be between 24-28% in WLS samples overall, • and 74% of patients seeking BPD/DS.	• Use physical signs and symptoms and labs (Table 5): ○ ↓ serum or urinary zinc or RBC zinc
Copper	• Routine pre-WLS screening of copper using serum copper and ceruloplasmin is recommended	• Prevalence of copper deficiency is	• Serum copper and ceruloplasmin

Micronutrient	Pre-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
	for patients prior to RYGB or BPD/DS, but results must be interpreted with caution. (Grade D, BEL 4) ☑ • Erythrocyte superoxide dismutase is the preferred assay for determining copper status in patients who have WLS. It is a more precise biomarker for screening of copper deficiency; when it is available and affordable. (Grade D, BEL 4) ☑	reported to be as high as 70% in pre-BPD women.	are recommended for screening indices, but are acute phase reactants (APR), and thus affected by inflammation, age, anemia, and medications.

Recommendations were formulated for each question within each micronutrient with reference to the previous guidelines. Once this was completed, grades A through D (strongest to weakest) were assigned to the recommendations by following the AACE protocol (see Appendix B-E).
* "Routine pre-WLS screening" refers to acquiring a nutrient baseline prior to weight loss surgery (WLS);
** "Routine post-WLS screening" refers to performing a nutrient assessment every 3-6 months in the first year and annually thereafter, unless otherwise specified.
☑ New recommendation since 2008 [1] is noted by ☑, otherwise there is no change in the current recommendation.

Table 2: Post-WLS Nutrient Screening Recommendations

Micronutrient	Post-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
Thiamin	• Routine post-WLS screening** is recommended for high-risk WLS groups (Grade B, BEL 2) ☑: o Patients with risk factors for TD (Grade B, BEL 2) ☑ o Females (Grade B, BEL 2) ☑ o African Americans (Grade B, BEL 2) ☑ o Patients not attending a nutritional clinic after surgery (Grade B, BEL 2) ☑ o Patients with GI symptoms (intractable nausea and vomiting, jejunal dilation, mega-colon, or constipation) (Grade B, BEL 2)☑ o Patients with concomitant medical conditions such as cardiac failure (especially those receiving furosemide) o Patients with SBBO (Grade C, BEL 3) ☑ • If signs and symptoms or risk factors are present in post-WLS patients, thiamin status should be assessed at least during the first 6 months, then every 3-6 months until symptoms resolve. (Grade B, BEL 2) ☑	• Prevalence of thiamin deficiency (TD) post-WLS ranges from < 1 to 49% and varies by type of WLS and post-WLS time frame.	• Risk of TD in WLS patients increases with other risk factors: malnutrition, excessive and/or rapid weight loss, and excessive alcohol use.
Vitamin B12	• Routine post-WLS screening of vitamin B12 status is recommended patients who have undergone RYGB, SG, or BPD/DS patients. (Grade B, BEL 2) ☑ • More frequent screening (e.g., every 3 months) is recommended in the first post-WLS year, and then at least annually or as clinically indicated for patients who are chronically using	• Prevalence of B12 deficiency post-WLS at 2-5 yrs is < 20% in RYGB and 4-20% in SG.	• Vitamin B12 deficiencies can occur due to food intolerances or restricted intake of protein and vitamin B12-containing foods.

Micronutrient	Post-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
	medications that exacerbate risk of B12 deficiency: nitrous oxide, neomycin, metformin, colchicine, PPIs, and seizure medications. (Grade B, BEL 2) ☑ • Serum B12 may not be adequate to identify B12 deficiency. It is recommended to include serum MMA with or without homocysteine to identify metabolic deficiency of B12 in symptomatic or asymptomatic patients and in those patients with history of B12 deficiency or pre-existing neuropathy. (Grade B, BEL 2) ☑		
Folate	• Routine post-WLS screening of folate status is recommended in all patients. (Grade B, BEL 2) ☑ • Particular attention should be given to female patients of childbearing age. (Grade B, BEL 2) ☑	• Prevalence of folate deficiency is reported in up to 65% patients post-WLS.	• Poor dietary intake of folate-rich foods and suspected non-adherence with multivitamin may contribute to folate deficiency.
Iron	• Routine post-WLS screening of iron status is recommended within three months after surgery, and then every 3-6 months until 12 months, and annually for all patients. (Grade B, BEL 2) ☑ • Iron status in post-WLS patients should be monitored at regular intervals using an iron panel, complete blood count, total iron-binding capacity, ferritin and soluble transferrin receptor (if available), along with clinical signs or symptoms. (Grade C, BEL 3) ☑ • Additional iron screening in post-WLS patients should be conducted as warranted by clinical signs or symptoms and or laboratory findings, or in other instances in which a deficiency is	• Prevalence of iron deficiency is reported to occur in post-WLS patients from 3 months to10 years: AGB 14%, SG <18%, RYGB 20-55% BPD 13-62% DS 8-50%	• Post-WLS iron deficiency can occur after any WLS procedure, despite routine supplementation .

Micronutrient	Post-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
	suspected. (Grade B, BEL 2) ☑		
Vitamin D and Calcium	• Routine post-WLS screening of vitamin D status is recommended for all patients. (Grade B, BEL 2) ☑ • More research is needed to establish a recommendation regarding the use of vitamin D binding protein assays as an additional tool for determining Vitamin D status in post-WLS patients. (Grade C, BEL 3) ☑	• Prevalence of vitamin D deficiency is reported to occur in up to 100% post-WLS patients.	• 25(OH)D is the preferred biochemical assay of vitamin D. • Elevated PTH levels • Increased bone formation/resorption markers
Vitamins A,E,K	• Post-WLS patients should be screened for vitamin A deficiency within the first post-operative year, particularly those who have undergone BPD/DS, regardless of symptoms. (Grade B, BEL 2) ☑ • Vitamin A should be measured in patients who have undergone RYGB and BPD/DS, particularly in those patients with evidence of protein-calorie malnutrition. (Grade B, BEL 2) • While vitamin E and K deficiencies are uncommon after WLS, patients who are symptomatic should be screened. (Grade B, BEL 2) ☑	• Prevalence of vitamin A deficiency is reported to occur in up to 70% of patients with RYGB and BPD/DS within 4 years post-WLSly. Deficiences of vitamins E, K are uncommon after WLS.	
Zinc	• Post- RYGB and post-BPD/DS patients should be screened at least annually for zinc deficiency. (Grade C, BEL 3) ☑ • Serum or plasma zinc are the most appropriate biomarkers for zinc screening in both pre-op zinc screening of post-WLS patients. (Grade C, BEL 3) ☑ • Zinc should be evaluated in all post-WLS patients when the patient is symptomatic for iron deficiency anemia, but screening results for iron deficiency anemia is negative. (Grade C, BEL 3) ☑ • Post-WLS Patients who have chronic diarrhea should be evaluated for zinc deficiency.	• Prevalence of zinc deficiency occurs in: up to 70% post-BPD/DS 40% post-RYGB 19% post-SG 34% post-AGB	• Deficiency of zinc is possible, even if taking zinc supplements and especially if primary sites of absorption (duodenum and proximal jejunum) are bypassed.

Micronutrient	Post-WLS Nutrient Screening Recommendation	Rationale	Other Considerations
	(Grade D, BEL 4) ☑		
Copper	• Routine post-WLS screening of copper status is recommended at least annually after BPD/DS and RYGB, even in the absence of clinical signs or symptoms of deficiency. (Grade C, BEL 4) ☑ • In post-WLS patients, serum copper and ceruloplasmin are the recommended biomarkers for determining copper status, as they are closely correlated with physical symptoms of copper deficiency. (Grade C, BEL 4) ☑	• Prevalence of copper deficiency is reported to be as high as 90% of patients post-BPD/DS and 10-20% post-RYGB. • Only 1 case report noted for post-SG copper deficiency; no data reported for post-AGB patients.	

* "Routine pre-WLS screening" refers to acquiring a nutrient baseline pre-WLS;
** "Routine post-WLS screening" refers to performing a nutrient assessment every 3-6 months in the first year and annually thereafter, unless otherwise specified.
☑ New recommendation since 2008 [1] is noted by ☑, otherwise there is no change in the current recommendation.

Table 3: Supplement Recommendations to Prevent Post-WLS Micronutrient Deficiency

Vitamin B1 (Thiamin)

Thiamin supplementation above the RDA is suggested to prevent thiamin deficiency:
All post-WLS patients should take at *least* 12 mg thiamin daily (Grade C, BEL 3) and preferably a 50 mg dose of thiamin from a B-complex supplement or multivitamin once or twice daily (Grade D, BEL 4) to maintain blood levels of thiamin and prevent TD. ☑

Vitamin B12 (Cobalamin)

All post-WLS patients should take vitamin B12 supplementation. (Grade B, BEL 2) ☑
Supplement dose for vitamin B12 in post-WLS patients varies based on route of administration (Grade B, BEL 2): ☑

Orally by disintegrating tablet, sublingual, or liquid: 350-500 mcg daily

Nasal spray: as directed by manufacturer

Parenteral (IM or SQ): 1000 mcg monthly

Folate (Folic Acid)

Post-WLS patients should take 400-800 mcg oral folate daily from their multivitamin. (Grade B, BEL 2) ☑
Women of childbearing age should take 800-1000 mcg oral folate daily. (Grade B, BEL 2) ☑

Iron

Post-WLS patients at low risk (males and patients without history of anemia) for post-WLS iron deficiency should receive at least 18 mg of iron from their multivitamin. (Grade C, BEL 3) ☑
Menstruating females and patients who have undergone RYGB, SG or BPD/DS should take at least 45-60mg of elemental iron daily (cumulatively, including iron from all vitamin and mineral supplements). (Grade C, BEL 3) ☑
Oral supplementation should be taken in divided doses separately from calcium supplements, acid-reducing medications, and foods high in phytates or polyphenols. (Grade D, BEL 3)
☑ Recommendation is downgraded to D, since majority of evidence is from non-WLS patients.

Vitamin D and Calcium

All post-WLS patients should take calcium supplementation. (Grade C, BEL 3) ☑
The appropriate dose of daily calcium from all sources, varies by surgical procedure:

BPD/DS: 1800-2400 mg/day
LAGB, SG, RYGB: 1200-1500 mg/day
The recommended preventative dose of vitamin D in post-WLS patients should be based on serum vitamin D levels:
Recommended vitamin D3 dose is 3000 IU daily, until blood levels of 25(OH)D are greater than sufficient (30 ng/mL) (Grade D, BEL 4) ☑
A 70-90% lower vitamin D3 bolus dose is needed (compared to vitamin D2) to achieve the same effects as those produced in healthy non-bariatric surgical patients (Grade A, BEL 1) ☑
In order to enhance calcium absorption in post-WLS patients (Grade C, BEL 3): ☑
Calcium should be given in divided doses
Calcium carbonate should be taken with meals
Calcium citrate may be taken with or without meals

Vitamins A, E, & K

Post-WLS patients should take vitamins A, E, K, with the dosage based upon type of procedure:
LAGB: Vitamin A dose (5000 IU/d) and Vitamin K dose (90-120 ug/day).(Grade C, BEL 3) ☑
RYGB, and SG: Vitamin A dose (5000-10,000 IU/d) and (Vitamin K dose (90-120 ug/day)(Grade D, BEL 4) ☑
LAGB, SG, RYGB, BPD/DS: Vitamin E dose (15 mg/d) (Grade D, BEL 4) ☑
DS: Additional supplementation of vitamin A (10,000 IU/d) and vitamin K (300 μg/d) is recommended (Grade B, BEL 2)☑
Higher maintenance doses of fat-soluble vitamins may be required for post-WLS patients with a previous history of deficiency in vitamin A, E, or K. (Grade D, BEL 4)
Special attention should be paid to post-WLS supplementation of vitamin A and K in pregnant women. (Grade D, BEL 3) ☑

Zinc

All post-WLS patients should take zinc with the dosage based upon type of procedure (Grade C, BEL 3): ☑
BPD/DS: Multivitamin with minerals containing 200% of the RDA (16-22 mg/day)
RYGB: Multivitamin with minerals containing 100-200% of the RDA (8-22 mg/day)
SG/LAGB: Multivitamin with minerals containing 100% of the RDA (8-11 mg/day)
To minimize the risk of copper deficiency in post-WLS patients, it is recommended that the supplementation protocol contain a ratio of 8-15 mg of supplemental zinc per 1 mg of copper. (Grade C, BEL 3) ☑
Formulation and composition of zinc supplements should be considered in post-WLS patients in order to calculate accurate levels of elemental zinc provided by the supplement. (Grade D, BEL 4) ☑

Copper

All post-WLS patients should take copper as part of routine multivitamin and mineral supplementation, with dosage based upon type of procedure (Grade C, BEL 3): ☑
BPD/DS or RYGB: 200% of the RDA (2 mg/day)

SG or LAGB: 100% of the RDA (1 mg/day)

In post-WLS patients, supplementation with 1 mg copper is recommended for every 8-15 mg of elemental zinc to prevent copper deficiency. (Grade C, BEL 3) ☑
In post-WLS patients, copper gluconate or sulfate is the recommended source of copper for supplementation. (Grade C, BEL 3) ☑

☑ New recommendation since 2008 [1] is noted by ☑, otherwise there is no change in the current recommendation.

Table 4: Repletion Recommendations for Post-WLS Micronutrient Deficiency

Thiamin

- Practitioners should treat post-WLS patients with a suspected thiamin deficiency before or in the absence of laboratory confirmation of deficiency, AND monitor and evaluate resolution of signs and symptoms. (Grade C, BEL 3) ☑
- Repletion dose for TD varies based on route of administration and severity of symptoms:
    - *Oral therapy*: 100 mg orally two-to -three times daily until symptoms resolve (Grade D, BEL 4) ☑
    - *IV therapy:* 200 mg, three times daily to 500 mg once or twice daily for 3-5 days followed by 250 mg/day for 3-5 days or until resolutions of symptoms, then consider treatment with 100 mg/day orally, usually indefinitely or until risk factors have been resolved (Grade D, BEL 4) ☑
    - *IM therapy*: 250 mg once daily for 3-5 days or 100-250 mg monthly (Grade C, BEL 3) ☑
- Simultaneous administration of magnesium, potassium and phosphorus should be given in patients at risk for refeeding syndrome. (Grade C, BEL 3) ☑

Vitamin B12 (Cobalamin)

- Post-WLS patients with a B12 deficiency should take 1000 mcg per day to achieve normal levels and then resume dosages recommended to maintain normal levels. (Grade B, BEL 2) ☑

Folate (Folic Acid)

- All post-WLS patients with folate deficiency should take an oral dose of 1000 mcg daily of folate to achieve normal levels and then resume recommended dosage to maintain normal levels. (Grade B, BEL 2) ☑
- Folate supplementation above 1 mg per day is not recommended in post-WLS patients, due to the potential masking of vitamin B12 deficiency. (Grade B, BEL 2)

Table 4: Repletion Recommendations for Post-WLS Micronutrient Deficiency

Iron

- In post-WLS patients with post-WLS iron deficiency, oral supplementation should be increased to provide from 150-200mg of elemental iron daily to amounts as high as 300 mg 2-3 times daily. (Grade C, BEL 3)
- Oral supplementation should be taken in divided doses separately from calcium supplements, acid-reducing medications, and foods high in phytates or polyphenols. (Grade D, BEL 3) Recommendation is downgraded to D, since majority of evidence is from non-WLS patients.
- If iron deficiency does not respond to oral therapy, intravenous iron infusion should be administered. (Grade C, BEL 3)

Vitamin D and Calcium

- Vitamin D levels must be repleted if deficient or insufficient in order to normalize calcium. (Grade C, BEL 3) ☑
- All post-WLS patients with vitamin D deficiency or insufficiency should be repleted with the following doses:
    - Vitamin D3 dosages of at least 2000 IU/day and as high as 6000 IU/day, or 50,000 IU vitamin D2 once to three times weekly (Grade A, BEL 1) ☑
    - Vitamin D3 is recommended as a more potent treatment than vitamin D2 when comparing frequency and amount needed for repletion. However, both forms can be efficacious, depending on the dosing regimen (Grade A, BEL 1) ☑
- The recommendations for repletion of calcium deficiency varies by surgical procedure (Grade C, BEL 3):
    - *BPD/DS:* 1800-2400 mg/day calcium
    - *LAGB, SG, RYGB:* 1200-1500 mg/day calcium ☑

Vitamin A

- In post-WLS patients with vitamin A deficiency without corneal changes: a dose of Vitamin A 10,000-25,000 IU/d should be administered orally until clinical improvement is evident (1-2 weeks). (Grade D, BEL 4)
- In post-WLS patients with vitamin A deficiency with corneal changes: a dose of Vitamin A 50,000-100,000 IU should be administered IM for 3 days, followed by 50,000 IU/day IM for 2 weeks. (Grade D, BEL 4)
- Post-WLS patients with vitamin A deficiency should also be evaluated for concurrent iron and/or copper deficiencies, as these can impair resolution of vitamin A deficiency. (Grade D, BEL 4)

Vitamin E

- The optimal therapeutic dose of vitamin E in post-WLS patients has not been clearly defined. There is potential for antioxidant benefits of vitamin E to be achieved with supplements of 100-400 IU/d. This is higher than the amount typically found in a multivitamin; thus, additional vitamin E supplementation may be required for repletion. (Grade D BEL 4)

Vitamin K

- For post-WLS patients with acute malabsorption, a parenteral dose of 10 mg Vitamin K is recommended. (Grade D, BEL 4)
- For post-WLS patients with chronic malabsorption, the recommended dosage of vitamin K is either 1-2 mg/d orally or 1-2 mg/week parenterally. (Grade D, BEL 4)

Table 4: Repletion Recommendations for Post-WLS Micronutrient Deficiency
Zinc • There is insufficient evidence to make a dose-related recommendation for repletion. The previous recommendation of 60 mg elemental zinc, orally twice a day, needs to be re-evaluated in light of emerging research that this dose may be inappropriate. • Repletion doses of zinc in post-WLS patients should be chosen carefully to avoid inducing a copper deficiency. (Grade D, BEL 3) ☑ • Zinc status should be routinely monitored using consistent parameters throughout the course of treatment. (Grade C, BEL 3) ☑
Copper • In post-WLS patients with a copper deficiency, the recommended regimen for repletion of copper will vary with the severity of the deficiency (Grade C, BEL 3): ☑ o *Mild to moderate deficiency* (including low hematological indices): Treat with 3 to 8 mg/day oral copper gluconate or sulfate until indices return to normal o *Severe deficiency*: 2 to 4 mg/day of intravenous copper can be initiated for six days or until serum levels return to normal and neurological symptoms resolve • Once copper levels are normal: Monitor copper levels every 3 months (Grade C, BEL 3) ☑

☑ New recommendation since Aills, et al., 2008 is noted by ☑, otherwise there is no change in the current recommendation.

Table 5: Signs and Symptoms of Micronutrient Deficiencies

Normal Lab Ranges	**Additional Laboratory Indices**	**Critical Range**	**Signs and Symptoms of Deficiency, including Nutrition-Focused Physical Assessment (NFPA)**
B1 (Thiamin)			
• Plasma Thiamin by HPLC: 4-15 nmol/L * • Whole blood /erythrocyte	• ETKA or TDP stimulation or activity coefficient: 1.16 and 1.20 (16-20%) are considered moderately deficient	• ETKA >1.25 (25%) are considered to be at moderate to high risk of deficiency	**Early Signs/Symptoms:** • *Dry beriberi (without edema):* brisk tendon reflexes, peripheral neuropathy and/or polyneuritis (with or without parasthesias); muscle weakness and/or pain of upper and lower extremities; gait ataxia;

[RBC] thiamin via HPLC: 2.5-7.5 µg/dL or 74-222 nmol/L ** • TDP: 70-180 nmol/L • Transketolase: >150 nmol/L • Erythrocyte transketolase activity (ETKA) or activity coefficients <1.15 (0-15%) indicate low risk of thiamin deficiency *Low sensitivity and specificity ** Erythrocytes contain 80-90% of total B1	• Transketolase: 120-150 nmol/L = marginal thiamin status ↑Pyruvate or lactate(lactic acidosis) • ↓Urinary Thiamin	• TDP < 70 nmol/L • Transketolase concentration: <120 nmol/L (deficiency) • ETKA or TDP stimulation or activity coefficient: >1.20 (>20%) = deficient • Urinary thiamin<40 µg or <27 µg/g creatinine	convulsions • *Wet beriberi:* heart failure with high cardiac output; edema in the lower extremities; tachycardia or bradycardia; lactic acidosis; dyspnea; heart hypertrophy and dilatation (particularly of the right ventricle); respiratory distress; systemic venous hypertension; bounding arterial pulsations • *Other/ Gastroenterologic:* Slow gastric emptying; nausea; vomiting; jejunal dilatation or megacolon; constipation **Advanced Signs/Symptoms:** • *Wernicke's encephalopathy (WE):* polyneuropathy & ataxia; ocular changes (opthalmoplegia & nystagmus); confabulation; short term memory loss; • If psychosis and/or hallucinations are present, also known as *Korsakoff psychosis (KP) and/or Wernicke-Korsakoff Syndrome (WKS).* **NFPA:** numbness, tingling in extremities could denote neuropathy, gait ataxia, convulsions, edema, vomiting, opthalmoplegia, nsytagmus, confusion, confabulation, hallucinations, psychosis
B12 (Cobalamin)			
• Serum B12 (cobalamin) 200-1,000 pg/mL	• ↑Serum Methylmalonic Acid (MMA)	• Serum B12: <200 pg/mL	**Early Signs/Symptoms:** • Pernicious anemia (due to absence of intrinsic factor)/

	• ↑Serum Homocysteine (tHcy)	deficiency <400 pg/mL suboptimal sMMA> 0.376 umol/L tHcy > 13.2 umol/L	Megaloblastic anemia; pale with slightly icteric skin and eyes; glossitis, magenta or 'beefy red' tongue, fatigue; anorexia; diarrhea • Numbness and paresthesia (tingling or prickly feeling) in extremities ataxia (poor muscle coordination); changes in reflexes, demyelination and axonal degeneration, especially of peripheral nerves, spinal cord, and cerebrum • Light-headedness or vertigo; shortness of breath • Tinnitus (ringing in ear) • Palpitations; rapid pulse **Advanced Signs/Symptoms:** • Angina or symptoms of congestive failure • Altered mental status, ranging from mild irritability and forgetfulness to severe dementia or frank psychosis **NFPA:** sore tongue; smooth and 'beefy red' tongue (magenta tongue), pale skin, slightly icteric skin and eyes; fatigue, numbness and tingling in extremities could denote neuropathy, gait ataxia dementia, psychosis
Folate			

• Red Blood Cell (RBC) • Folate 340-1020 ng/mL age > 18 yrs	• Urinary formiminoglutamic acid (FIGLU) • Normal Serum and Methylmalonic Acid (MMA) • ↑Serum Homocysteine (tHcy)	• RBC Folate <305 nmol/L deficiency • < 227 nmoll/L anemia	**NFPA:** changes in pigmentation, or ulceration, of skin, nails, or oral mucosa
• **Iron**			
• Iron Panel, Ferritin, CBC, transferrin, transferrin saturation • Serum iron: 60-170 ug/dL • Transferrin 200-360 ug/dL • Transferrin Saturation/ TSat:20-50% • Ferritin: 12-300 ng/mL (male) • Ferritin: 12-150 ng/mL (female) • **NOTE**: Ferritin fluctuates with inflammation, age and infection.	• ↑TIBC • UIBC • sTFR • Stage 1: Serum ferritin ↓ 20 ng/mL • Stage 2: Serum iron ↓50 g/dL; transferrin saturation <16% • Stage 3: Anemia with normal-appearing RBCs and indexes occur • Stage 4: Microcytosis, then hypochromia • Stage 5: Fe deficiency affects tissues, resulting in signs and symptoms	• Iron <50ug/dL • Ferritin <20ug/dL • TIBC >450ug/dL	• Fatigue; decreased work performance; impaired learning ability • Microcytic Anemia • Decreased immune function; enteropathy • Glossitis, dysphagia; • Spoon-Shaped Nails (koilonychias); Vertical Ridges on Nails • Rapid heart rate/palpitations; **NFPA:** Glossitis, Spoon-shaped nails, Vertical Ridges
Calcium			
• Serum PTH • 25(OH)D	• iPTH > 65 pg/mL indicates ↓calcium • serum calcium (poor indicator	• Serum calcium should be WNL (9-10.5 mg/dL) patients	• Leg cramping, Tetany • Hypocalcemia, • Neuromuscular hyper-excitability • Muscle Weakness • Osteoporosis

	of bone stores • ionized calcium corrects for low albumin • ↑Urinary N-and C- telopeptide • ↑Urinary cross-links type 1 collagen telopeptides (indicator of bone resorption) • DXA scan findings baseline in pre-post menopausal • DXA every 2 yrs	without renal disease	**NFPA**: typically only present in toddlers as Rickets.
Vitamin D			
• -↓25(OH)D >30 ng/ml (> 75 nmol/L) sufficiency • May see ↑Serum PTH (PTH Adult < 65 pg/mL WNL)	• ↓Serum phosphorus • ↑Alkaline phosphatase • ↓Urinary calcium • ↓serum estradiol post RNY with • ↓intestinal calcium absorption and ↑N-telopeptide (marker of bone resportion) • ↑osteocalcin (marker for bone formation)	• Insufficiency: 20-30 ng/mL (50-75 nmol/L) • Deficiency: <20 ng/mL (<50 nmol/L)	• Hypocalcemia; tetany; tingling; cramping • Metabolic bone disease; rachitic tetany **NFPA:** typically only present in toddlers as Rickets.
Vitamin A			

• Plasma Retinol 20-80 ug/dL	• Retinol Binding Protein	• Plasma retionol <10 µg/dL	**Early Signs/Symptoms:** • Nyctalopia (night blindness or difficulty seeing in dim light); Bitot's spots (foamy white spots on sclera of eye); endophthalmitis; poor wound healing. • Hyperkeratinization of the skinLoss of taste (vitamin A and zinc metabolism in interrelated) • **Advanced Signs/Symptoms:** • Corneal damage; xerosis; keratomalcia; perforation; • Blindness; xerosis **NFPA:** Bitot's spots, poor wound healing, hyperkeratosis, xerosis
Vitamin E			
• Plasma alpha tocopherol	• Plasma lipids	• <5µg/mL	• Hyporeflexia; disturbances of gait; Neurologic damage; muscle weakness, decreased proprioception and vibration • Opthalmoplegia;nystagmus; nyctalopia • RBC hemolysis (Hemolytic Anemia) NFPA: gait ataxia, hyporeflexia/weakness, nystagmus, opthalmoplegia, Ceroid deposition in muscle;
Vitamin K			
• Prothrombin Time (PT) 10-13 sec • PT is not a	• ↑DCP ↓Plasma phylloquinone	• Variable	**Early Signs/Symptoms:** ○ Hemorrhage due to deficiency of prothrombin and other

sensitive measure of vitamin K status 1 nmol/l			factors; ○ Easy bruising; bleeding gums; delayed blood clotting, heavy menstrual or nose bleeding **Advanced Symptoms:** ○ Osteoporosis (due to the interrelationships between vitamin K and bone metabolism) **NFPA:** skin hemorrhages (Petechia, Purpura, Ecchymosis [bruising])
Zinc			
• Plasma zinc 60-130 ug/dL	• Decreased serum zinc • Decreased erythrocyte zinc (RBC zinc) • Decreased urinary zinc • Physical signs and symptoms	< 70 ug/dL for women < 74 ug/dL for men	**Early (Mild to Moderate)** **Symptoms:** • Rash; acne; • Hypogeusia or ageusia (change in or without taste); • Immune deficiencies; increased infections; • Infertility; • Growth retardation; delayed sexual maturation **Advanced (Severe)** **Symptoms:** • Hypogonadism; • Alopecia (hair loss); • Skin lesions/ rashes (bullous pustualr dermatitits, acrodermatitis enteropathica); • Diarrhea; • Impaired appetite/anorexia; • Night blindness • Recurrent infections; and delayed wound healing **NFPA**: alopecia, skin lesions, delayed wound healing

Copper			
• Serum or plasma copper -11.8-22.8 mmol/L • Ceruloplasmin 75-145ug/dL	• Decreased erythrocyte superoxide dismutase activity • 24 hour urine copper	<10 ìmol/L <75 ug/dL	**Early Signs/Symptoms:** • Hypochromic anemia; Neutropenia, Pancytopenia • Hair, skin and nails Hypopigmentation • Hypercholesterolemia; • Impaired biomarkers of bone metabolism **Advanced Signs/Symptoms:** • Gait abnormalities **NFPA:** Hypopigmentation of skin, hair or nails • peripheral neuropathies; and myelopathies

Table 6: Nutrient Supplementation for Patients with WLS and Without WLS

Nutrients	**Non-WLS**		**WLS Preventative Supplements**			
	Dietary Reference Intake (DRI)	**Tolerable Upper Intake Level (UL) Daily Value (DV)**	**AGB**	**LSG**	**RYGB**	**BPD/DS**
Vit B 1	1.2 mg/d 14 yrs+ M 1.1 mg/d 19 yrs+ F	**UL:** none set; no reports of adverse effects from >50 mg B1/d from food or supplements **DV: 1.5**	At least 12 mg/d At risk patients: at least 50 -100mg/d			
Vit B 12	2.4 ug/d 14 yrs+ M,F	**UL:** none set; due to its low potential for toxicity **DV: 6 ug**	350-500 mcg/day PO or As directed – nasal or 1000 mcg/mo IM			
Folate	400 ug/d 19 yrs+ M,F	**UL:** 1000 mcg all ages & pregnancy **DV: 400 ug**	400-800 mcg oral 800-1000 mcg F childbearing ages			

Nutrients	Non-WLS		WLS Preventative Supplements			
	Dietary Reference Intake (DRI)	**Tolerable Upper Intake Level (UL) Daily Value (DV)**	**AGB**	**LSG**	**RYGB**	**BPD/DS**
Calcium	1000 mg/d 19-50 yrs M,F 200 mg/d 51 yrs+ F	**UL:** 2000-3000 mg /d **DV:** 1000 mg	1200-1500 mg/d			1800-2400 mg/d
Vit A	900 ug/d 14 yrs+ M; 700 ug/d 14 yrs+ F	**UL:** 10,000 IU/d (3000 mcg RAE/d)* retinol **DV:** 5000 IU	5000 IU/d		5000-10,000 IU/d	10,000 IU/d
Vit E	15 mg/d 14 yrs+ M,F	**UL:** 1000 mg/d (1500 IU/d) **DV:** 30 mg	15 mg/d			
Vit K	120 ug/d 19 yrs+ M 90 ug/d 19 yrs+ F	**UL:** No UL established due to its low potential for toxicity. **DV:** 80 ug	90-120 ug/d			300 ug/d
Vit D	600 IU/d (15 ug/d) 14 yrs+ M,F	**UL:** 4000 IU/d (100 ug/d) **DV:** 400 IU	At least 3000 IU/d to maintain D,25(OH) levels > 30 ng/mL			
Iron	8 mg/d 19 yrs+ M 8 mg/d 51 yrs+ F 18 mg/d 19-50 yrs F	**UL:** 45 mg/d **DV**: 18 mg	At least 18 mg/d from multivitamin		At least 45-60 mg/d (from all sources) in F with menses	
Zinc	11 mg/d 19 yrs+ M 8 mg/d 19 yrs+ F	**UL:** 40 mg/d **DV:** 15mg	8-11 mg/d		8-11 mg/d to 16-22 mg/d	16-22 mg/d
Copper	900 ug/d 19 yrs+ M,F	**UL:** No UL established; toxicity reported with grams of ingested copper **DV**: 2 mg	1 mg/d		1-2 mg/d	2 mg

Supplementation for non-WLS patients: Dietary Reference Intake (DRI), Daily Value (DV), Tolerable Upper Intake Level (UL) Supplementation for WLS patients: Actual dose for nutrients by type of WL